NORA MEDINA: Open Payments
NPI 1023782448 · WESLACO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,493 in 39 payments from 7 companies in 2025. Trend: 2023 $1,331 · 2024 $2,094 · 2025 $1,493
Food & beverage: $1,493
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. | 12 | $486 |
| Lilly USA, LLC | 8 | $335 |
| ABBVIE INC. | 4 | $263 |
| Novo Nordisk Inc | 11 | $236 |
| Otsuka America Pharmaceutical, Inc. | 1 | $120 |
| Amgen Inc. | 2 | $33 |
| Astellas Pharma US Inc | 1 | $20 |
Products named: Dexcom G6 Transmitter, ZEPBOUND, Ozempic, VRAYLAR, QULIPTA, REXULTI, DEXCOM G7 GSS (161), JARDIANCE.
Industry payments across TX — which companies pay providers there.
